Lumos Pharma, Inc. (LUMO) NASDAQ
4.34
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.34
+0(+0.00%)
Currency In USD
| Previous Close | 4.34 |
| Open | 4.33 |
| Day High | 4.34 |
| Day Low | 4.33 |
| 52-Week High | 4.58 |
| 52-Week Low | 1.37 |
| Volume | 390,873 |
| Average Volume | 102,979 |
| Market Cap | 37.54M |
| PE | -1.01 |
| EPS | -4.28 |
| Moving Average 50 Days | 4.23 |
| Moving Average 200 Days | 3.1 |
| Change | 0 |
Data not available
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma
GlobeNewswire Inc.
Dec 12, 2024 1:47 PM GMT
AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Venture
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
GlobeNewswire Inc.
Nov 21, 2024 2:00 PM GMT
AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
GlobeNewswire Inc.
Oct 30, 2024 8:05 PM GMT
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210